Thrombophilia: Implications for pregnancy outcome

Thrombosis Research

Volumn 109, Issue 2-3, 2003, Pages 73-81

  Greer, Ian A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Growth restriction; Miscarriage; Pre eclampsia; Pregnancy; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FETUS WASTAGE; FIBRINOLYSIS; GENETIC DISORDER; GENETIC SCREENING; HEALTH CARE COST; HERITABILITY; HUMAN; HYPERCOAGULABILITY; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SPONTANEOUS ABORTION; THROMBOCYTE; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0037464820     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00095-1     Document Type: Review

References (78)

1. Clarke P., Brennand J., Conkie J.A., McCall F., Greer I.A., Walker I.D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb. Haemost. 79:1998;1166-1170.
2. Stirling Y., Woolf L., North W.R.S.et al. Haemostasis in normal pregnancy. Thromb. Haemost. 52:1984;176.
3. Hellgren M., Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium: I. Normal condition. Gynecol. Obstet. Invest. 12:1981;141.
4. Persson B.L., Stenberg P., Holmberg L.et al. Transamidating enzymes in maternal plasma and placenta in human pregnancies complicated by intrauterine growth retardation. J. Dev. Physiol. 2:1980;37.
5. Bachman F. Plasminogen-plasmin enzyme system. Colman R.W., Hirsh J., Marder V.J., Clowes A.W., George J.N. Haemostasis and thrombosis. Basic principles and clinical practice. 2001;275-320 Lippincott Williams and Wilkins, Philadelphia.
6. Halligan A., Bonnar J., Sheppard B.et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br. J. Obstet. Gynaecol. 101:1994;488.
7. Eichinger S., Weltermann A., Philipp K.et al. Prospective evaluation of haemostatic system activation and thrombin potential in healthy pregnant women with and without Factor V Leiden. Thromb. Haemost. 82:1999;1232-1236.
8. Holmes V.A., Wallace J.M.W., Gilnmore W.S.et al. Tisssue factor expression on monocyte subpopulations during normal pregnancy. Thromb. Haemost. 87:2002;953-958.
9. Comp P.C., Thurneau G.R., Welsh J., Esmon C.T. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 68:1986;881.
10. Bonnar J., McNicol G.P., Douglas A.S.et al. Coagulation and fibrinolytic mechanisms during and after normal childbirth. BMJ. 2:1970;200.
11. Booth N., Reith A., Bennett B.et al. A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy. Thromb. Haemost. 59:1988;77.
12. Lecander I., Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br. J. Haematol. 62:1986;221.
13. Nilsson I.M., Felding P., Lecander I.et al. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br. J. Haematol. 62:1986;215.
14. Bonnar J., McNicol G.P., Douglas A.S.et al. Fibrinolytic enzyme system and pregnancy. BMJ. 3:1969;387.
15. Beller F.K., Ebert C. The coagulation and fibrinolytic enzyme systems in normal pregnancy and the puerperium. Eur. J. Obstet. Gynecol. Reprod. Biol. 13:1982;177.
16. Cadroy Y., Grandjean H., Pichon J.et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br. J. Obstet. Gynaecol. 100:1993;416.
17. Chabloz P., Reber G., Boehlen F.et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br. J. Haematol. 115:2001;150-152.
18. Ballegeer V., Mombaerts P., Declerk P.J.et al. Fibrinolytic response to venous occlusion and fibrin fragment D-Dimer levels in normal and complicated pregnancy. Thromb. Haemost. 58:1987;1030.
19. Isacson S., Nilsson I.M. Defective fibrinolysis in blood and vein walls in recurrent idiopathic venous thrombosis. Acta Chir. Scand. 138:1972;313.
20. Gerbasi F.R., Bottoms S.S., Farag A.et al. Increased intravascular coagulation associated with pregnancy. Obstet. Gynecol. 75:1990;385.
21. Brenner B., Sarig G., Weiner Z., Younis J., Blumenfeld Z., Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb. Haemost. 82:1999;6-9.
22. Greer I. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 353:1999;1258-1265.
23. Triplett D.A., Harris E.N. Antiphospholipid antibodies and reproduction. Am. J. Reprod. Immunol. 21:1989;123-131.
24. Rai R.S., Clifford K., Cohen H., Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and anitiphospholipid antibodies. Hum. Reprod. 10:1995;3301-3304.
25. Vincent T., Rai R., Cohen H. Increased thrombin generation in women with recurrent miscarriage. Lancet. 352:1998;116.
26. De Wolf F., Carreras L.O., Moerman P.et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am. J. Obstet. Gynecol. 142:1982;829-834.
27. Out H.J., Kooijman C.D., Bruinse H.W., Derksen R.H. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipidantibodies. Eur. J. Obstet. Gynecol. Reprod. Biol. 41:1991;179-186.
28. Rai R., Cohen H., Dave M.et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 314:1997;253-257.
29. Branch D.W., Silver R.M., Blackwell J.L., Reading J.C., Scott J.R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol. 80:1992;614-620.
30. Creagh M.D., Malia R.G., Cooper S.M., Smith A.R., Duncan S.L., Greaves M. Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss. J. Clin. Pathol. 44:1991 (Jan.);45-47.
31. Backos M., Rai R., Baxter N., Chilcott I.T., Cohen H., Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br. J. Obstet. Gynaecol. 106:1999;102-107.
32. Laude I., Rongieres-Bertrand C., Boyer-Neumann C.et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb. Haemost. 85:2001;18-21.
33. Wolf J. The nature and significance of platelet products in human plasma. Br. J. Haematol. 13:1967;269-288.
34. Warkentin T.E., Hayward C.P.M., Boshkov L.K., Santos A.V.et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 84:1994;3691-3699.
35. Mallat Z., Benamer H., Hugel B., Benessiano J.et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 101:2000;841-848.
36. Giesen P.L., Rauch U., Borhmann B., Kling D.et al. Blood-borne tissue factor: another view of thrombosis. Med. Sci. 96:1999;2311-2315.
37. Gilbert G.E., Sims P.J., Wiedemer T., Furie B.et al. Platelet-derived microparticles express high affinity receptors for Factor VIII. J. Biol. Chem. 266:1991;17261-17268.
38. Sims P.J., Faioni E.M., Wiedemer T., Shattil S.J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263:1988;18205-18212.
39. Barry O.P., Practico D., Lawson J.A., Fitzgerald G.A. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J. Clin. Invest. 99:1997;2118-2127.
40. Albanese J., Meterissian S., Kontogiannea M.et al. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood. 91:1998;3862-3874.
41. Sugimura M., Kobayashi T., Shu F.et al. Annexin V inhibits phosphatidyl-serine-induced intrauterine growth restriction in mice. Placenta. 20:1999;555-560.
42. Rand J.H., Wu X.-X., Andree H.A.M.et al. Pregnancy loss in the antiphospholipid-antibody-syndrome - a possible thrombogenic mechanism. N. Engl. J. Med. 337:1997;154-160.
43. Keularts I.M., Beguin S., de Swaan C.et al. Treatment with a BP11b/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb. Haemost. 80:1998;370-371.
44. Preston F.E., Rosendaal F.R., Walker I.D.et al. Increased fetal loss in women with heritable thrombophilia: European prospective cohort on thrombophilia (EPCOT). Lancet. 348:1996;913-916.
45. Sanson B.J., Friederich P.W., Simioni P.et al. The risk of abortion and stillbirth in antithrombin, protein C and protein S deficient women. Thromb. Haemost. 75:1996;387-388.
46. Brenner M., Mandel H., Lanir N. Activated protein C resistance can be associated with recurrent fetal loss. Br. J. Haematol. 97:1997;51-54.
47. Grandone E., Margagalione M., Colaizzo D.I. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb. Haemost. 77:1997;822-824.
48. Ridker P.M., Miletich J.P., Buring J.E.et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann. Intern. Med. 128:1998;1000-1003.
49. Brenner B. Inherited thrombophilia and fetal loss. Curr. Opin. Hematol. 7:2000;290-295.
50. Dizon-Townson D.S., Meline L., Nelson L.M.et al. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am. J. Obstet. Gynecol. 177(2):1997;402-405.
51. Meinardi J.R., Middeldorp S., de Kam P.J.et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann. Intern. Med. 130:1999;736-739.
52. Younis J.S., Brenner B., Ohel G.et al. Activated protein C resistance and factor V Leiden mutation can be associated with first - as well as second - trimester recurrent pregnancy loss. Am. J. Reprod. Immunol. 43:2000;31-35.
53. Gris J.C., Quere I., Monpeyroux F.et al. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study 5(NOHA5). Thromb. Haemost. 81:1999;891-899.
54. Martinelli I., Taioli E., Cetin I.et al. Mutations in coagulation factors in women with unexplained late fetal loss. N. Engl. J. Med. 343:2000;1015-1018.
55. Murphy R.P., Donoghue C., Nallen R.J.et al. Prospective evaluation of the risk conferred by Factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler. Thromb. Vasc. Biol. 20:2000;266-270.
56. Rai R., Backos M., Elgaddal S., Shlebak A., Regan L. Factor V Leiden and recurrent miscarriage - prospective outcome of untreated pregnancies. Hum. Reprod. 17(2):2002;442-445.
57. Kupferminc M.J., Eldor A., Steinman N.et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med. 340:1999;9-13.
58. Balasch J., Reverted J.C., Fabregues F.et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum. Reprod. 12(5):1997;1094-1097.
59. Foka Z.J., Lambropoulos A.F., Saravelos H.et al. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum. Reprod. 15(2):2000;458-462.
60. Gris J.C., Quere I., Monpeyroux F.et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb. Haemost. 81(6):1999;891-899.
61. Kutteh W.H., Park V.M., Deitcher S.R. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil. Steril. 71(6):1999;1048-1053.
62. Holmes Z.R., Regan L., Chilcott I.et al. The C677T MTHRF gene mutation is not predictive of risk for recurrent fetal loss. Br. J. Haematol. 105(1):1999;98-101.
63. Preston F.E., Rosendaal F.R., Walker I.D.et al. Thromboprophylaxis in pregnancy reduces fetal losses in women with heritable thrombophilia: a prospective EPCOT study. Thromb. Haemost. 1999;227S. [Abstract].
64. Brenner B. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb. Haemost. 83:2000;693-697.
65. Greer I.A. Procoagulant microparticles: new insights and opportunities in pregnancy loss? Thromb. Haemost. 85:2001;3-4.
66. Greer I.A. Pregnancy-induced hypertension. Chamberlain G.V.P., Steer P.J. Turnbull's obstetrics. 3rd ed. 2001;333-353 Churchill Livingstone, London.
67. Greer I.A. Platelets and coagulation abnormalities in pre-eclampsia. Rubin P. Handbook of hypertension: hypertension in pregnancy. 1999;163-181 Elsevier, Amsterdam.
68. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 353:1999;1258-1265.
69. Kupferminc M.J., Peri H., Zwang E.et al. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placenta and second trimester loss. Acta Obstet. Gynecol. Scand. 79:2000;963-967.
70. Martinelli P., Grandone E., Coliazzo D.et al. Familial thrombophilias and the occurrence of fetal growth restriction. Haematologica. 86:2001;428-431.
71. Alferivic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome. Eur. J. Obstet. Gynecol. Reprod. Biol. 101:2002;6-14.
72. Morrison E.R., Miedzybrodzka Z.H., Campbell D.et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb. Haemost. 87:2002;779-785.
73. Infante-Rivard C., Rivard G.E., Wagner V.Y.H.et al. Absence of association of thrombophilic polymorphism with intrauterine growth restriction. N. Engl. J. Med. 347:2002;19-25.
74. Glueck C.J., Kupferminc M.J., Fontaine R.N.et al. Genetic hypofibrinolysis in complicated pregnancies. J. Perinat. Med. 29(6):2001;528-534.
75. Clark P., Sattar N., Walker I.D.et al. The Glasgow Outcome, APCR and Lipid (GOAL) pregnancy study: significance of pregnancy associated activated protein C resistance. Thromb. Haemost. 85:2001;30-35.
76. Clark P., Walker I.D., Greer I.A. The acquired activated protein C resistance of pregnancy is associated with an increase in thrombin generation and is inversely associated with fetal weight. Lancet. 353:1999;292-293.
77. Clark P., Twaddle S., Walker I.D.et al. Cost effectiveness of screening for the Factor V Leiden mutation in pregnant women. Lancet. 359:2002;1919-1920.
78. Ginsberg J., Greer I.A., Hirsh J. Sixth ACCP consensus conference on antithrombotic therapy. Use of antithrombotic agents during pregnancy. Chest. 119:2001;122S-131S.